NCT06101667Active, not recruiting
Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)
Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window -- A Multicenter, Prospective, Open-label, Blind Endpoint, Randomized Controlled Trial（ANGEL-BAO）
Source: ClinicalTrials.gov · Last updated 22 Oct 2026
Brief summary (registry, in English)
The aim of this study is to assess the efficacy and safety of endovascular treatment versus medical management in patients with acute basilar artery occlusion with extended time window of 24-72 hours from onset.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 224 (actual)
- First submitted
- 15 Oct 2023
- Start date
- 16 Nov 2023
- Primary completion date
- 17 Mar 2026
- Lead sponsor
- Beijing Tiantan Hospital
- Diseases
- Stroke
- NCT number
- NCT06101667
What you commit to
- Study type: Interventional
- Participants enrolled: 224
- From 16 Nov 2023 to the primary completion date, 17 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any sign of intracranial hemorrhage (except microbleeds) on brain imaging prior to randomization
- Enrolled in another drug or device trial or expected to participate in another drug or device treatment trial within the following 3 months.
Other illness
- History of contraindication for contrast medium (except mild rash)
- Known to have dementia or psychiatric disease unable to complete neurological assessment and follow-up
- Any other condition (in the opinion of the site investigator) that inappropriate to participate this study
Other
- Complete cerebellar infarct with significant mass effect, or bilateral thalamic infarction as evidenced by baseline neuroimaging
- CT or MRI evidence of intracranial tumor (except small meningioma and cerebral aneurysm \< 3mm in diameter)
- Known or highly suspected chronic occlusion of basilar artery
- Current pregnant or breast-feeding
- Life expectancy is less than 3 months
Who the study is looking for
- Age≥18 years
- Acute basilar artery occlusion confirmed by CTA, MRA, or DSA
- Pre-stroke mRS of 0-2
- NIHSS score ≥ 10 before randomization
- Time interval from symptom onset (or last known well) to randomization within 24-72 hours
- Diffusion-weighted imaging(DWI)-based pc-ASPECTS ≥ 6 and Pons-Midbrain Index (PMI) ≤3
- Time from completion of DWI imaging to randomization is ≤3 hours
- Each patient or their legal representative must provide written informed consent before enrolment
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Tiantan Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.